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ABSTRACT: Background: Dopamine transmission is
involved in the maintenance of the structural plasticity of
direct-pathway and indirect-pathway striatal projection
neurons (d-SPNs and i-SPNs, respectively). The lack of
dopamine in Parkinson’s disease produces synaptic rem-
odeling in both types of SPNs, reducing the length of the
dendritic arbor and spine density and increasing the
intrinsic excitability. Meanwhile, the elevation of dopa-
mine levels by levodopa recovers these alterations selec-
tively in i-SPNs. However, little is known about the
specific role of the D1 receptor (D1R) in these alterations.
Methods: To explore the specific role of D1R in the syn-
aptic remodeling of SPNs, we used knockout D1R mice
(D1R−/−) and wild-type mice crossed with drd2-enhanced
green fluorescent protein (eGFP) to identify d-SPNs and
i-SPNs. Corticostriatal slices were used for reconstruc-
tion of the dendritic arbors after Lucifer yellow
intracellular injection and for whole-cell recordings in
naïve and parkinsonian mice treated with saline or
levodopa.
Results: The genetic inactivation of D1R reduces the
length of the dendritic tree and the spine density in all
SPNs, although more so in d-SPNs, which also increases
their spiking. In parkinsonian D1R−/− mice, the spine
density decreases in i-SPNs, and this spine loss recovers
after chronic levodopa.
Conclusions: D1R is essential for the maintenance of
spine plasticity in d-SPNs but also affects i-SPNs, indi-
cating an important crosstalk between these 2 types of
neurons. © 2020 International Parkinson and Movement
Disorder Society
Key Words: dopamine; Parkinson’s disease; spines;
striatum; synaptic plasticity
The striatum is a key component of the basal ganglia,
playing an important role in the control of motor
behavior.1 This nucleus is mainly composed of direct-
pathway striatal projection neurons (d-SPNs) and indi-
rect-pathway striatal projection neurons (i-SPNs),
expressing dopamine D1 and D2 receptors, respec-
tively.2 The striatum is densely innervated by dopami-
nergic inputs from the substantia nigra pars compacta
and ventral tegmental area and glutamatergic inputs
from the cortex and thalamus.2 Dopaminergic afferents
synapse onto SPNs, and the released dopamine acti-
vates dopamine receptors.3 D1R and D2R are
colocalized with glutamate receptors in the dendritic
spines and are critical for SPNs activity.4
Dopamine signaling in the striatum is implicated in
modulating synaptic plasticity in SPNs.5 The lack of
dopamine in Parkinson’s disease (PD) produces a pro-
found transformation in the basal ganglia circuits,
resulting in the loss of dendritic spines in SPNs6-15 and
an increase in SPNs excitability10,12,13,16,17 as a homeo-
static mechanism to maintain global activity. Adminis-
tration of the dopamine precursor levodopa (L-dopa)
after dopamine depletion selectively remodels i-SPNs
without affecting d-SPNs.10-12 However, chronic
L-dopa treatment induces dyskinesia, which is related to
D1R hypersensitization.15,18-23
High synaptic dopamine levels, such as those induced
by cocaine and amphetamines, increases the number of
dendritic spines and produces long-term adaptations in
SPN plasticity.24 During development, dopamine also
modulates spinogenesis and excitability in SPNs,25,26
and D1-like receptor agonists increase corticostriatal
activity and spine density in d-SPNs in a protein kinase
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A-dependent manner.27 Interestingly, dopamine pro-
motes spine enlargement in d-SPNs by D1R activa-
tion.28 However, the specific role of D1R in the
synaptic remodeling and spine profile of d-SPNs and i-
SPNs remains unknown. To establish the specific role
of D1R, we used D1R knockout mice (D1R−/−) crossed
with bacterial artificial chromosome-drd2-eGFP mice to
identify the SPNs. Although hyperactive, D1R−/− mice
exhibited impaired motor coordination and slightly
reduced basal dopamine.29-34 D1R inactivation blocks
hippocampal and corticostriatal long-term potentiation
and FosB induced by D1R agonists,19,35-37 suggesting
that striatal function is altered in D1R−/− mice.
We found that D1R inactivation reduces the neuronal
architecture and increases the intrinsic excitability of
d-SPNs, as with dopamine depletion. Strikingly, D1R
inactivation induces a small but consistent spine density
reduction in i-SPNs, which is potentiated after dopa-
mine depletion. We show that D1R has a critical role in
spine density and the intrinsic excitability of d-SPNs
but is also involved in i-SPN spine density.
Methods and Materials
Four-month-old or 5-month-old male and female
hemizygous BAC-transgenic mice (D2R-eGFP, C57BL/
6; wild type [WT] group) and D1R−/− D2R-eGFP mice
(D1R−/− group) were used. No sexual differences were
observed within any group, so the results were pooled.
All animal procedures were approved by the CSIC Ethi-
cal Committee and followed European Union Guide-
lines (2010/63/EU).
Striatal Lesion and Treatments
The 6-hydroxydopamine (6-OHDA) lesions and
L-dopa treatment were performed as described.11,12,19,38
11,12,19,38 Mice were sacrificed 1 hour after the last
L-dopa or saline injection. Some WT mice were treated
with reserpine (5 mg/kg) on 2 consecutive days (reser-
pine group; Supplementary Table 1).
Single-Cell Microinjection and Spine Analysis
The mice were anesthetized with pentobarbital (1 ml/
kg) and perfused fixed with 4% paraformaldehyde. For
SPN morphological reconstructions, we used 200 μm
sections. Identified SPNs were filled with 8% Lucifer
yellow (Sigma-Aldrich, Madrid, Spain) and injected
with a 10 to 20 nA hyperpolarizing current. The
d-SPNs (GFP negative) and i-SPNs (GFP positive)
located in the dorsolateral striatum (Supplementary
Fig. S1) were filled with Lucifer yellow, and 2-
dimensional representation of the complexity of the 3-
dimensional dendrite tree were analyzed using
Neurolucida v8 software (MicroBrightField, Williston,
VT).11-13 We analyzed 4 to 9 SPNs per animal
(Supplementary Table 1). Only completely filled neu-
rons were analyzed. Filled neurons near the lesion track
were discarded. For spine density analysis, we quanti-
fied the total spine number in 1 dendrite per SPN, usu-
ally one expanded in a horizontal plane (x-axis). The
researcher was blinded to the experimental conditions.
Whole-Cell Patch Clamp Recordings
The mice (Supplementary Table 2) were anesthetized
as noted previously and transcardially perfused with
ice-cold N-methyl-D-glucamine-HEPES. Coronal brain
slices (275 μm) were incubated for 60 minutes with a
recovery solution at room temperature before recording
with standard artificial cerebrospinal fluid solution at 31
to 32C. Identified dorsal striatum SPNs were recorded
with patch pipettes (5–8 MΩ) filled with intracellular
solution. Current-clamp (for intrinsic properties and fir-
ing rate experiments) or voltage-clamp (for excitatory
postsynaptic currents [EPSCs]) recordings were per-
formed as described (Supplementary Material).
Statistical Analysis
Data are expressed as mean per animal  standard
error of the mean. Statistical evaluations and graphs were
generated using SigmaPlot 12.0 (Systat-Software Inc., San
Jose, CA). Statistical differences (P < 0.05) were assessed
by t test and 1-way or 2-way analysis of variance
(ANOVA) followed by Bonferroni t test or Kruskal-Wallis
analysis followed by Dunn’s test for nonparametric data.
Results
The severe lack of striatal dopamine increases the
excitability and reduces the spine density in both types
of SPNs.11-13 Other authors observed increased excit-
ability in d-SNPs16,17 and a decrease in i-SPNs,10 indi-
cating that dopamine is important for the synaptic
regulation of SPNs; however, the precise role of D1R
or D2R in these processes is not well established. To
evaluate the role of D1R in the activity and morphol-
ogy of SPNs, we used D1R−/− mice crossed with BAC-
D2R-eGFP mice to identify d-SPNs (negative-eGFP)
and i-SPNs (positive-eGFP) compared with BAC-trans-
genic WT (D1R+/+) mice. We determined that the BAC-
transgene does not affect the phenotype of D1R−/−
mice. BAC-D1R−/− mice exhibited hyperlocomotion
and impaired motor coordination (Supplementary
Fig. 3) as described for D1R−/−.29,30,32 Tyrosine
hydroxylase protein-ir is similar in WT, BAC-D1R−/−,
and D1R−/− naïve mice, confirming previous data,33
and 6-OHDA lesions similarly affected striatal TH
levels in both types of mice. The FosB response after
L-dopa treatment was blunted in BAC-D1R−/− as in
D1R−/− mice19 (Supplementary Fig. 3).
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Inactivation of D1R Increases Spiking in
d-SPNs
Dopamine receptors have opposite roles in regulating
the spiking of SPNs: D1R increases the firing rate of
d-SPNs, whereas D2R reduces the rate in i-SPNs,39
although Lemos and colleagues40 saw no change in
i-SPN excitability after acute D2R agonist. However,
the lack of activation of both receptors in PD increases
the spiking in both SPNs.12,13,16,17 To determine the
exact role of D1R in the firing rate of SPNs, we studied
the frequency of the evoked action potentials in D1R−/−
mice. In d-SPNs, the number of evoked action poten-
tials increased in D1R−/− mice compared with WT mice
at all tested intensities (Fig. 1A), as in PD mouse
models.12,13 This increased firing rate correlates with
the decreased rheobase of d-SPNs compared to WT
(Table 1). Other action potential properties (threshold,
amplitude, or amplitude after the hyperpolarization
period) and passive membrane properties in D1R−/−
mice are similar to WT mice (Table 1). In contrast, the
inactivation of D1R in i-SPNs does not affect the num-
ber of evoked action potentials (Fig. 1A) or their intrin-
sic membrane properties (Table 1). In WT mice,
d-SPNs show fewer spikes than i-SPNs (Fig. 1A), as
shown previously.16,41-46 However, the specific increase
in the d-SPNs firing rate induced by D1R inactivation
drives both SPNs to exhibit similar spiking (Fig. 1A).
In PD models, using somatic stimulation, the lack of
dopamine reduces the threshold for evoked action
potentials specifically in d-SPNs.12 We studied whether
D1R inactivation reproduces this specific synaptic facili-
tation by evoking backpropagated action potentials in
the soma with increasing stimulation intensities. The
presynaptic fibers were stimulated with an electrode in
the white matter. d-SPNs in D1R−/− mice had a lower
spike threshold than in WT mice (Fig. 1B), and no
change was observed in i-SPNs (Fig. 1B). This differ-
ence facilitates EPSP-spike generation in d-SPNs relative
to i-SPNs.
Genetic Inactivation of D1R Reduces the
Dendritic Tree in Both Types of SPNs
Severe lack of striatal dopamine reduces dendritic tree
complexity in PD model animals.10,11,47,48 To deter-
mine the role of D1R in these changes, we studied the
impact of D1R genetic inactivation on dendritic arbor
complexity in both types of SPNs. In D1R−/− mice, den-
dritic tree length is reduced in both d-SPNs and i-SPNs
compared with WT (Fig. 2A) and is homogeneous
along the dendritic arbor, shown by Sholl analysis. The
number of nodes was not reduced in either type of
SPNs (data not shown). The shrinkage is not attributed
to the loss of primary dendrites because d-SPNs and
i-SPNs of D1R−/− mice have the same number of
primary dendrites as WT with a similar maximum den-
dritic order (data not shown).
To compare the effect of D1R genetic inactivation
with acute dopamine depletion, we treated a group of
WT mice with reserpine. In D1R−/− and reserpine-
treated WT mice, the total dendritic length was similar
in d-SPNs (1966.37 μm  150.11 in D1R−/− and
1796.88 μm  264.53 in WT-reserpine mice; data not
shown) and i-SPNs (1989.02 μm  156.02 in D1R−/−
and 1640.88 μm  62.51 in reserpinized WT mice;
data not shown). Therefore, the genetic inactivation of
D1R reduces the complexity of dendritic arborization
in both types of SPNs similarly to acute dopamine
depletion.
Genetic Inactivation of D1R Reduces Spine
Density in Both Types of SPNs
Lack of dopamine causes the loss of spines in both types
of SPNs.11-14,48,49 We studied the role of D1R in these
changes and whether they affect 1 or both SPNs types. In
D1R−/− mice, the spine density of d-SPNs is reduced by
34% relative to WT (Fig. 2B), with 5.37  0.19 and
8.14  0.56 spines per 10 μm in D1R−/− and WT mice,
respectively. This reduction is observed in proximal and
distal dendritic parts, demonstrated by Sholl analysis
(Fig. 2). Spine density is also reduced in i-SPNs, although
at a much lower reduction (14%) than in d-SPNs (Fig. 2C),
with 6.66  0.18 spines per 10 μm between 45 to 120 μm
from soma in D1R−/− versus 7.77  0.41 in WT mice
(Fig. 2B,C). Therefore, D1Rs are primarily involved in
spine maintenance in d-SPNs, but also play a significant
role in i-SPNs.
Striatal Glutamate Release Does Not Change in
D1R−/− Mice
The spine loss observed in PD could represent a neu-
roprotective mechanism of SPNs to reduce synaptic
contacts in response to elevated glutamate in the stria-
tum.50 Because D1R−/− mice exhibit an increased gluta-
mate/glutamine cycle,32 we determined if spine loss in
i-SPNs was caused by increased striatal glutamatergic
synaptic transmission. We studied synaptic glutamate
release by measuring the paired-pulse ratio (PPR) and
the spontaneous EPSCs in the presence of picrotoxin
(100 μM) to avoid the influence of GABAergic trans-
mission. For PPR, we evoked 2 consecutive EPSCs 100
milliseconds apart. In WT mice, i-SPNs exhibit higher
facilitation than d-SPNs (Supplementary Fig. 4A) as
previously shown43; genetic D1R inactivation did not
modify the PPR in i-SPNs (Supplementary Fig. 4A;
1.35  0.05 and 1.23  0.08 for D1R−/− and WT,
respectively) or d-SPNs (1.04  0.07 and 0.98  0.08 for
D1R−/− and WT, respectively; Supplementary Fig. 4A).
This indicates that presynaptic glutamatergic release does
not change in D1R−/− mice. An analysis of sEPSC at a
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SPN membrane potential of −70 mV showed no differ-
ences in amplitude, frequency, or probability of interevent
interval between d-SPNs and i-SPNs in WT mice, as
previously found.51 No changes were caused by D1R inac-
tivation (Supplementary Fig. 4B), indicating no changes in
glutamatergic synaptic release in D1R−/− mice.
FIG. 1. Genetic D1 receptor inactivation increases the excitability of d-SPNs. (A) Representative whole-cell recordings showing SPNs recorded at 0.2
nA (top). Frequency of action potential evoked with depolarizing current in d-SPNs and i-SPNs (bottom). Histograms show the mean firing rate at 0.3
nA to facilitate the comparison between d-SPNs with i-SPNs. *P < 0.05; 2-way analysis of variance following Bonferroni posttest. (B) Illustrative traces
of action potentials evoked by synaptic stimulation in WT and D1R−/− mice. Summary of changes in the threshold of synaptically evoked action poten-
tials. **P < 0.005; 1-way analysis of variance following Bonferroni posttest. D1R−/−, knockout D1 receptor mice; d-SPNs, direct-pathway striatal projec-
tion neurons; i-SPNs, indirect-pathway striatal projection neurons; SPNs, striatal projection neurons; WT, wild type. [Color figure can be viewed at
wileyonlinelibrary.com]
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Dopamine Depletion Does Not Change
Dendritic Length in D1R−/− Mice
Inactivation of D1R reduces the dendritic length of
both types of SPNs. To understand how dopaminergic
transmission affects the arborization of SPNs, we deter-
mined if dopamine acts via D1R by assessing if dopa-
mine depletion further reduces dendritic length in
D1R−/− mice. We studied the morphology of SPNs in
6-OHDA-lesioned D1R−/− mice (Supplementary
Table 1) in the totally denervated striatum. The com-
plexity of the dendritic arbor did not change after the
lesion; there were no changes in the Sholl analysis of
the dendritic length in either d-SPNs or i-SPNs (Fig. 3A).
Chronic administration of L-dopa, the main treatment
for PD, does not alter the dendritic tree of SPNs in 6-
OHDA-lesioned D1R−/− mice. Therefore, a severe lack
of dopamine does not alter dendritic arborization more
than that induced by D1R inactivation, and subsequent
D2R stimulation with L-dopa in D1R−/− does not pro-
duce additional changes.
Dopamine Depletion Does Not Alter the Spine
Loss Induced in d-SPNs by D1R Inactivation,
but Potentiates This Loss in i-SPNs
We next studied if the spine loss induced by D1R
inactivation is further potentiated by dopamine deple-
tion. In d-SPNs, the lack of dopamine in 6-OHDA-
lesioned D1R−/− mice does not further reduce the spine
density compared with naïve D1R−/− mice (5.26  0.26
vs. 5.37  0.19 spines per 10 μm in 6-OHDA-lesioned
and naïve D1R−/− mice, respectively; Fig. 3B). There-
fore, inactivation of D1R is sufficient to reduce the
spine density in d-SPNs. However, in i-SPNs, the spine
loss induced by D1R inactivation is not as robust as in
d-SPNs, and dopamine depletion further decreases
spine density (Fig. 3B) compared with naïve D1R−/−
mice. This spine loss was observed in proximal and dis-
tal dendritic parts, shown by Sholl analysis, is similar
to that observed in WT mice treated with 6-OHDA or
treated with reserpine11-12 o with reserpine
(4.61  0.28 vs. 4.96  0.56 spines/10 μm, in
6-OHDA-lesioned D1R−/− and reserpinized WT,
respectively). Therefore, in d-SPNs, the impact of
D1R inactivation is similar to dopamine depletion,
but in i-SPNs, the effect of D1R on spine density is
potentiated by dopamine depletion.
In D1R−/− Mice, L-dopa Treatment Restores the
Spine Loss Induced by Lesions in i-SPNs, but
Not in d-SPNs
L-dopa treatment in PD animals selectively restores
spine density in i-SPNs.10-13 In D1R−/− mice, L-dopa
does not change spine density in d-SPNs (Fig. 3B) and
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6.68  0.22 spines/10 μm in D1R−/− lesioned mice
treated with saline or L-dopa, respectively), but it is
unable to restore the spine loss caused by D1R inactiva-
tion (Fig. 3B). Notably, the spine density recovery
induced by L-dopa in i-SPNs in lesioned D1R−/− mice
does not reach the density values observed in WT-
lesioned mice treated with L-dopa (6.68  0.22 vs.
7.59  0.40 spines/10 μm in D1R−/− vs WT mice;
P < 0.05 1-way ANOVA), but density recovers to that
observed in D1R−/− naïve mice (Fig. 3B). The spine
FIG. 2. Genetic D1 receptor inactivation reduces the dendritic tree complex and the spine density in both types of SPNs. (A) Illustrations of Sholl analy-
sis of SPNs (top). Total length and Sholl analysis of the total dendritic length of d-SPNs and i-SPNs (bottom). (B) Representative confocal images of
dendrites of SPNs and Sholl analysis of the spine density of SPNs. (C) Average of spine density (45–120 μm from the soma) to facilitate the comparison
between d-SPNs with i-SPNs. *P < 0.05, **P < 0.01, ***P < 0.001 WT versus D1R−/−; 2-way analysis of variance following Bonferroni posttest. D1R−/−,
knockout D1 receptor mice; d-SPNs, direct-pathway striatal projection neurons; i-SPNs, indirect-pathway striatal projection neurons; SPNs, striatal
projection neurons; WT, wild type. [Color figure can be viewed at wileyonlinelibrary.com]
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recovery is not attributed to L-dopa treatment alone
because in nonlesioned D1R−/− and WT mice treated
with L-dopa for 15 days, spine density does not change
in either d-SPNs or i-SPNs (data not shown). These
results indicate that in i-SPNs, D1R, and D2R help reg-
ulate the spine maintenance.
FIG. 3. The spine density of i-SPNs of D1R−/− mice decreases with dopamine depletion and recovers after L-dopa treatment. (A) Illustrations of Sholl analysis
of SPNs in D1R−/− mice in each experimental condition (top). Total length and Sholl analysis of the total dendritic length of d-SPNs (left) and i-SPNs (right) in
naïve or 6-OHDA-lesioned D1R−/− mice treated with saline or L-dopa. (B) Representative confocal images of dendrites of SPNs in naïve, lesion, and lesion
plus L-dopa D1R−/− mice. Sholl analysis of the spine density of SPNs. Histograms show the average spine density between 45 to 120 μm from soma in naïve
and dyskinetic WT mice in comparison to naïve and 6-OHDA-lesioned D1R−/− mice treated with saline or L-dopa. *P < 0.05, **P < 0.01, ***P < 0.001; 2-way
analysis of variance following Bonferroni posttest. Note: WT mice (gray trace) and naïve D1R−/− mice (open circles) shown in Figure 2 are included to facilitate
the comparison. 6-OHDA, 6-hydroxydopamine; D1R−/−, knockout D1 receptor mice; d-SPNs, direct-pathway striatal projection neurons; i-SPNs, indirect-
pathway striatal projection neurons; L-dopa, levodopa; SPNs, striatal projection neurons; WT, wild type. [Color figure can be viewed at wileyonlinelibrary.com]
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L-dopa Treatment Reverses the
Hyperexcitability in i-SPNs Caused by
Dopamine Depletion
Chronic L-dopa induces an imbalance between the
intrinsic excitability of the 2 types of SPNs in 6-
OHDA-lesioned mice, favoring d-SPNs.10,12,13 We mea-
sured the firing rate in 6-OHDA-lesioned D1R−/− mice
treated with L-dopa. In d-SPNs, the firing rate did not
change after L-dopa (Fig. 4A). The passive membrane
properties and action potential properties are similar in
d-SPNs in lesioned mice and naïve D1R−/− mice
(Table 1). However, in i-SPNs the firing rate is higher
in lesioned mice compared with naïve D1R−/− mice at
all tested intensities (F2,127 = 17.39; P < 0.01, 2-way
ANOVA; Fig. 4), similar to observations in parkinso-
nian WT mice.12,13 After L-dopa treatment, the firing
rate reverts to naïve values (Fig. 4), overlapping with
the slight increase of the rheobase, despite the threshold
decrease of the action potential (Table 1). In lesioned
D1R−/− mice, the spiking is lower in d-SPNs than in
i-SPNs (Fig. 4C; P < 0.05 2-way ANOVA). After
L-dopa, both SPNs exhibit a similar firing rate (Fig. 4C),
unlike dyskinetic WT animals, whose d-SPNs exhibit
more spikes than i-SPNs.12,13 Therefore, D1R inactiva-
tion blocks the increased firing rate induced in d-SPNs
by L-dopa, matching the firing rate observed in i-SPNs.
Discussion
Our goal was to unravel the role of dopamine D1
receptors in the electrophysiological and structural plas-
ticity of SPNs. In d-SPNs, genetic inactivation of D1R
reduces dendritic tree length and spine density and
increases firing rate, similar to changes caused by dopa-
mine depletion in WT animals. Remarkably, D1R inac-
tivation also affects i-SPNs, reducing dendritic tree
complexity and spine density, although the spine loss is
less severe than in d-SPNs and the firing rate of i-SPNs
is unchanged. In D1R−/− mice, dopamine depletion
does not further change d-SPNs, but in i-SPNs,
FIG. 4. L-dopa restores the hyperexcitability produced by dopamine depletion in i-SPNs in D1R−/− mice. (A) Representative whole-cell recordings show-
ing SPNs in D1R−/− mice recorded at 0.2 nA. (B) Frequency of the action potential evoked with depolarizing current in d-SPNs and i-SPNs. Note: The
values of naïve D1R−/− mice shown in Figure 1 are included to facilitate the comparison. (C) Histograms show the mean firing rate at 0.3 nA to facilitate
the comparison between d-SPNs with i-SPNs in 6-OHDA-lesioned D1R−/− mice treated with saline or L-dopa. *P < 0.05, **P < 0.005; 2-way analysis of
variance following Bonferroni posttest. 6-OHDA, 6-hydroxydopamine; D1R−/−, knockout D1 receptor mice; d-SPNs, direct-pathway striatal projection
neurons; i-SPNs, indirect-pathway striatal projection neurons; L-dopa, levodopa; SPNs, striatal projection neurons. [Color figure can be viewed at
wileyonlinelibrary.com]
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dopamine depletion increases spine loss and spiking.
Dopamine replacement does not affect d-SPNs, but
spine loss and spiking induced by the lesions are recov-
ered in i-SPNs.
D1R Inactivation Reduces Spine Density and
Dendritic Arbor Complexity in SPNs
Dopamine is essential for the morphological mainte-
nance of SPNs; in human patients with PD and animal
models, a lack of dopamine reduces dendritic tree com-
plexity and spine density.8,24,52 The specific role of
D1R on the dendritic arbor of d-SPNs and i-SPNs has
not been explored. We demonstrated that genetic inacti-
vation of D1R and dopamine depletion similarly alter
the dendritic length and spine density of d-SPNs.
Although the exact mechanisms are unclear, neonatal
P1-2 SPNs treated with D1R or D2R agonists or
cocultured with mesencephalic dopaminergic or cortical
neurons increase the formation and maturation of den-
dritic spines.53-55 In addition, studies in neonates (P8-
13) showed that in d-SPNs, D1R activation increases
spine density, accelerates its formation,27 and enlarges
the spines when coactivated with glutamatergic
inputs,28 suggesting a cooperative role of D1R and glu-
tamate during d-SPN spine development.
Genetic inactivation of D1R also reduces the length
of the dendritic tree and spine density of i-SPNs, even
though these neurons only express D2R. The reduction
of the dendritic arbor in i-SPNs is similar in naïve and
6-OHDA-lesioned D1R−/− mice, which could indicate
that D1R is important for i-SPN dendritic length. Previ-
ous studies have implicated D2R in the maintenance of
the dendritic arbor of SPNs,56 so the lack of D1R dur-
ing striatal development could occlude the additional
shrinkage induced by the toxin, masking the role of
D2R in adult mice. However, the precise mechanisms
underlying D1R inactivation-induced spine reduction in
i-SPNs remain unknown. One likely mechanism that
could explain spine decrease in both SPNs is a reduced
corticostriatal glutamatergic transmission through the
basal ganglia circuit caused by D1R inactivation.
Indeed, in P14-15 mice, silencing γ-Aminobutyric acid
release in d-SPNs, a downstream effect of D1R inacti-
vation, reduces spine density in d-SPNs and i-SPNs by
reducing corticostriatal glutamate release at the circuit
level.25 Although we do not detect changes in synaptic
glutamate release in D1R−/− mice, we cannot exclude a
decreased glutamatergic innervation as a consequence
of D1R inactivation, and in fact, we favor this interpre-
tation. In addition, it is also possible that the spine loss
we observed using our constitutive D1R−/− mice is
attributed to compensatory mechanisms during devel-
opment. However, in Pitx3−/− mice showing a severe
lack of dopamine neurons, dorsal striatal SPNs develop
without dopamine signaling and nevertheless respond
to a dopaminergic stimulus (L-dopa) in the same way as
SPNs lesioned with 6-OHDA at adulthood.13 This
observation argues against a developmental deficit and
supports the key role of D1R in the morphological
maintenance of SPNs. Further experiments are needed
using conditional-D1R−/− mice to rule out this
possibility.
Reserpine treatment induces a severe parkinsonian
syndrome and causes spine pruning affecting both types
of SPNs, as in PD models and agreeing with our stud-
ies11-13 and others,8,14,57 but disagreeing with some
others.7,10 Recently, Graves and Surmeier49 found spine
loss in d-SPNs longer after lesion, although other
groups find it earlier.57
Chronic L-dopa treatment selectively recovers the 6-
OHDA-induced loss of dendritic spines in i-SPNs.10-13
We found that L-dopa induces no changes in the spine
density of d-SPNs in lesioned-D1−/− mice, similar to
WT animals. L-dopa rescues the spine loss caused by
6-OHDA in i-SPNs, but not the loss caused by D1R
inactivation. This effect suggests that D1R and D2R
cooperate in the maintenance and formation of spines
in i-SPNs, agreeing with previous results.53,55
Excitability of SPNs Is Imbalanced in
D1−/− Mice
Dendritic spines contribute to functional and plastic
changes in brain networks. In PD, the loss of dendritic
spines is compensated for by increasing the intrinsic
excitability of SPNs.12,13,16,17 Genetic inactivation of
D1R reduces spine density, increases the firing rate, and
decreases the threshold for action potentials induced by
synaptic stimulation of d-SPNs, as in PD models. D2R
overexpression decreases dendritic arbor length in both
SPNs while increasing their excitability via potassium
channels.56 The intrinsic excitability does not change in
i-SPNs, despite the reduction of spine density and the
length of the dendritic tree, so higher atrophy may be
necessary. At 50% spine loss, as in 6-OHDA-lesioned
D1R−/− mice, the intrinsic excitability of i-SPNs
increases. Alternatively, the activation of D2R main-
tains i-SPNs spiking in a physiological range in D1R−/−
mice. The nigrostriatal pathway is not altered in D1R−/−
mice, allowing dopamine, via D2R, to decrease the excit-
ability of i-SPNs. The hyperexcitability of d-SPNs could
block the increased firing rate of i-SPNs. The classic
model proposing the relative independence of the striatal
pathways has recently been revised. Electrophysiology
and calcium-imaging data indicate functional interac-
tions between d-SPNs and i-SPNs, which form neuronal
clusters or ensembles during specific aspects of motor
behavior,58-69 either by direct intrastriatal influence
(SPN-SPN) via interneurons, or multisynaptic connec-
tions with the motor cortex. Direct synaptic connections
of d-SPNs to i-SPNs is supported by anatomical data
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revealing that collaterals synapses from d-SPNs to
i-SPNs are weak.70,71 However, recent research has
shown that these connections strongly inhibit the other
SPNs when there are multiple activations.72 In D1R−/−
mice, the hyperexcitability of d-SPNs could be enough to
block i-SPN hyperexcitability. Alternatively, increased
spiking of d-SPNs observed in D1R−/− mice could acti-
vate striatal interneurons responsible for reducing the
excitability of i-SPNs. Further experiments will resolve
this issue because fast-spiking or cholinergic interneurons
regulate the excitability of SPNs, and their activation is
modified in PD.57,73,74
In physiological conditions, d-SPNs are less active
than i-SPNs,13,16,41-46 whereas in PD models, the spik-
ing of both types of SPNs is similar.12,13,16,17 The
genetic inactivation of D1R increases the excitability of
d-SPNs, driving both striatal pathway neurons to a sim-
ilar activation state. Although D1R−/− mice lack dopa-
mine, this does not alter the spiking in d-SPNs, the
firing rate and the spine loss are increased in i-SPNs,
and L-dopa treatment selectively recovers the spiking
rate in i-SPNs, similarly activating both neurons.
D1R−/− mice do not develop dyskinesia,19 so L-dopa-
induced dyskinesia could be related to the higher acti-
vation of d-SPNs in WT-lesioned mice.
In summary, dendritic arborization and excitability
of d-SPNs are similarly altered by D1R deletion or by
dopamine depletion; i-SPNs are slightly affected by
D1R deletion but strongly affected by dopamine deple-
tion. Dopamine replacement in 6-OHDA-lesioned
D1R−/− mice partially restores spine density in i-SPNs,
but not in d-SPNs. This highlights a pivotal role for
D1R in the structural plasticity of both types of SPNs
and reveals how D1R regulates synaptic transmission
related to PD.
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